| Literature DB >> 32454945 |
Lu Lyu1, Shuli He2, Huabing Zhang1, Wei Li1, Jingbo Zeng3, Fan Ping1, Yu-Xiu Li1.
Abstract
This study is aimed at evaluating the relationship between leukocyte telomere length (LTL) and mitochondrial DNA copy number (mtDNAcn) in a noninterventional rural community of China with different glucose tolerance statuses. In addition, we investigate whether the indicators of oxidative stress and inflammation were involved and identify mediators among them. A total of 450 subjects in rural China were included and divided into two groups according to a 75 g oral glucose tolerance test (OGTT): the abnormal glucose metabolism (AGM, n = 257, 57.1%) group and the normal glucose tolerance (NGT, n = 193, 42.9%) group. Indicators of oxidative stress (superoxide dismutase (SOD) and glutathione reductase (GR)) and inflammatory indices (tumor necrosis factor α (TNFα) and interleukin-6 (IL-6)) were all determined by ELISA. LTL and mtDNAcn were measured using a real-time PCR assay. Linear regressions were used to adjust for covariates that might affect the relationship between LTL and mtDNAcn. Mediation analyses were utilized to evaluate the mediators. In the AGM, LTL was correlated with mtDNAcn (r = 0.214, p = 0.001), but no correlation was found in the NGT. The association between LTL and mtDNAcn was weakened after adjusting for inflammatory factors in the AGM (p = 0.087). LTL and mtDNAcn were both inversely related to HbA1c, IL-6, TNFα, and SOD activity. Mediation analysis demonstrated that TNFα was a significant mediator in the telomere-mitochondrial interactome in the AGM. This result suggests that inflammation and oxidative stress may play a vital role in telomere shortening as well as mitochondrial dysfunction. In the subjects with hyperglycemia, a significant positive correlation is observed between LTL and mtDNAcn, which is probably mediated by TNFα. TNFα may be considered a potential therapeutic target against aging-related disease in hyperglycemia.Entities:
Mesh:
Substances:
Year: 2020 PMID: 32454945 PMCID: PMC7222557 DOI: 10.1155/2020/8235873
Source DB: PubMed Journal: Oxid Med Cell Longev ISSN: 1942-0994 Impact factor: 6.543
Clinical and demographic characteristics in groups with different glucose tolerance statuses.
| Parameter | NGT ( | AGM ( |
|
|---|---|---|---|
| Age (years) | 49 ± 11.26 | 55.21 ± 10.21 | ≤0.001∗∗ |
| Sex, male : female† | 62 : 131 | 97 : 160 | 0.120 |
| BMI (kg/m2) | 25.31 ± 3.55 | 26.64 ± 3.85 | ≤0.001∗∗ |
| Waist circumference (cm) | 84.94 ± 9.93 | 88.83 ± 9.88 | ≤0.001∗∗ |
| Hip circumference (cm) | 90.08 ± 9.93 | 88.83 ± 9.88 | ≤0.001∗∗ |
| SBP (mmHg) | 125.03 ± 19.00 | 130.36 ± 19.26 | 0.004∗ |
| DBP (mmHg) | 75.70 ± 9.43 | 76.4 ± 10.52 | 0.486 |
| HbA1c% | 5.3 (5.1, 5.6) | 5.90 (5.5, 6.6) | ≤0.001∗∗ |
| HOMA-IR | 2.22 (1.54, 3.07) | 3.23 (2.16, 4.99) | ≤0.001∗∗ |
| HOMA- | 91.32 (67.99, 130.56) | 65.09 (41.08, 98.29) | ≤0.001∗∗ |
| FPG (mmol/L) | 5.46 (5.22, 5.72) | 6.57 (6.13, 7.90) | ≤0.001∗∗ |
| 2hPG (mmol/L) | 6.03 (5.04, 6.89) | 9.7 (7.83, 14.83) | ≤0.001∗∗ |
| TC (mmol/L) | 5.30 ± 0.1 | 5.68 ± 0.1 | ≤0.001∗∗ |
| TG (mmol/L) | 1.20 (0.78, 1.66) | 1.71 (1.13, 2.36) | ≤0.001∗∗ |
| HDL-C (mmol/L) | 1.29 (1.11, 1.50) | 1.25 (1.08, 1.44) | 0.050 |
| LDL-C (mmol/L) | 2.71 ± 0.07 | 2.99 ± 0.07 | ≤0.001∗∗ |
| GR (U/L) | 7.20 ± 3.22 | 7.00 ± 3.33 | 0.538 |
| SOD activity (U/mL) | 60.69 ± 18.51 | 59.57 ± 18.57 | 0.46 |
| IL-6 (pg/mL) | 3.96 ± 3.33 | 3.98 ± 2.93 | 0.932 |
| TNF | 23.96 ± 10.32 | 23.93 ± 10.67 | 0.977 |
| LTL | 28.72 ± 0.83 | 28.67 ± 0.851 | 0.583 |
| mtDNAcn | 108.88 ± 44.31 | 100.47 ± 41.04 | 0.023∗ |
∗ p < 0.05; ∗∗p < 0.01; †chi-square test. NGT: normal glucose tolerance; AGM: abnormal glucose metabolism; BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; HOMA-IR: homeostatic model assessment of insulin resistance; HOMA-β: homeostasis model assessment of insulin secretion; FPG: fasting plasma glucose; 2hPG: 2 h postprandial plasma glucose; TC: cholesterol; TG: triglyceride; HDL-C: high-density lipoprotein; LDL-C: low-density lipoprotein; GR: glutathione reductase; SOD: superoxide dismutase; IL-6: interleukin-6; TNFα: tumor necrosis factor α; LTL: telomere length; mtDNAcn: mitochondrial DNA copy number.
Figure 1Correlation analysis between mtDNAcn and LTL in populations with different glucose tolerance statuses: (a) correlation analysis between mtDNAcn and LTL in the NGT (r = 0.071, p = 0.325) and (b) correlation analysis between mtDNAcn and LTL in the AGM (r = 0.214, p = 0.001).
Correlation analysis between LTL and mtDNAcn in a correction model of abnormal glucose metabolism.
| Correction model | Unstandardized coefficients ( | Standardized coefficients ( |
|
|
|---|---|---|---|---|
| M1 | 11.884 | 0.245 | 0.073 | ≤0.001∗∗ |
| M2 | 11.232 | 0.224 | 0.074 | 0.001∗∗ |
| M3 | 6.237 | 0.125 | 0.112 | 0.087 |
| M4 | 11.813 | 0.242 | 0.106 | ≤0.001∗∗ |
Model 1 (M1): adjusted for age and gender. Model 2 (M2): adjusted for antioxidants (GR and SOD activity) based on Model 1. Model 3 (M3): adjusted for inflammatory (IL-6 and TNFα) based on Model 1. Model 4 (M4): adjusted for lipid metabolism indicators (TC, TG, HDL-C, LDL-C) based on Model 1. ∗p < 0.05; ∗∗p < 0.01.
Correlation analysis of antioxidants and inflammatory indicators with glucose metabolism indices in the AGM.
| HbA1c% |
| FPG (mmol/L) |
| 2hPG (mmol/L) |
| HOMA-IR |
| HOMA- |
| |
|---|---|---|---|---|---|---|---|---|---|---|
| GR (U/L) | -0.086 | 0.199 | -0.052 | 0.436 | -0.022 | 0.745 | 0.012 | 0.864 | 0.027 | 0.687 |
| SOD activity (U/mL) | -0.037 | 0.587 | -0.161 | 0.016∗ | -0.13 | 0.052 | -0.105 | 0.12 | 0.055 | 0.416 |
| IL-6 (pg/mL) | -0.012 | 0.858 | -0.09 | 0.179 | -0.03 | 0.66 | 0.014 | 0.831 | 0.098 | 0.150 |
| TNF | 0.247 | ≤0.001∗∗ | -0.059 | 0.379 | 0.16 | 0.017∗ | 0.036 | 0.595 | 0.045 | 0.510 |
∗ p < 0.05; ∗∗p < 0.01. FPG: fasting plasma glucose; 2hPG: 2 h postprandial plasma glucose; HOMA-IR: homeostatic model assessment of insulin resistance; HOMA-β: homeostasis model assessment of insulin secretion; GR: glutathione reductase; SOD: superoxide dismutase; IL-6: interleukin-6; TNFα: tumor necrosis factor α.
Figure 2Correlation analysis between HbA1c and LTL and mtDNAcn: (a) correlation analysis between HbA1c and LTL (r = ‐0.174, p ≤ 0.001) and (b) correlation analysis between HbA1c and mtDNAcn (r = ‐0.085, p = 0.072).
Correlation analysis of antioxidants and inflammatory indicators with LTL and mtDNAcn.
| LTL |
| mtDNAcn |
| |
|---|---|---|---|---|
| GR (U/L) | -0.064 | 0.205 | 0.011 | 0.833 |
| SOD activity (U/mL) | -0.229 | ≤0.001∗∗ | -0.139 | 0.006∗∗ |
| IL-6 (pg/mL) | -0.133 | 0.008∗∗ | -0.144 | 0.004∗∗ |
| TNF | -0.477 | ≤0.001∗∗ | -0.236 | ≤0.001∗∗ |
∗ p < 0.05; ∗∗p < 0.01. GR: glutathione reductase; SOD: superoxide dismutase; IL-6: interleukin-6; TNFα: tumor necrosis factor α; LTL: telomere length; mtDNAcn: mitochondrial DNA copy number.
Figure 3Mediational analysis of antioxidants and inflammatory indicators on the relationship between LTL and mtDNAcn after adjusting for age and gender. (a) a1: the effect of LTL on GR (p = 0.251); b1: the effect of GR on mtDNAcn (p = 0.925); a1 × b1: mediating effect of GR on mtDNAcn; c′1: the direct effect of LTL on mtDNAcn after the correction of GR (p = 0.001). (b) a2: the effect of LTL on SOD activity (p = 0.032); b2: the effect of SOD activity on mtDNAcn (p = 0.472); a2 × b2: mediating effect of SOD activity on mtDNAcn; c′2: the direct effect of LTL on mtDNAcn after the correction of SOD activity (p = 0.001). (c) a3: the effect of LTL on IL-6 (p = 0.002); b3: the effect of IL-6 on mtDNAcn (p = 0.415); a3 × b3: mediating effect of IL-6 on mtDNAcn; c′3: the direct effect of LTL on mtDNAcn after the correction of IL-6 (p = 0.001). (d) a4: the effect of LTL on TNFα (p ≤ 0.001); b4: the effect of TNFα on mtDNAcn (p = 0.002); a4 × b4: mediating effect of TNFα on mtDNAcn; c′4: the direct effect of LTL on mtDNAcn after the correction of TNFα (p = 0.058).